This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis | MicrobiomeTrials
← Back to trials NCT03952637
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis Recruiting PHASE1, PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2019-08-19Est. Completion: 2030-01-01
Enrollment target: 54 participantsLocations National Institutes of Health Clinical Center, Bethesda, Maryland, United States Other microbiome trials you might be interested in Lysosomal Storage Disorders Gaucher Disease Parkinson Disease
The purpose of this study is to identify genetic, biochemical, and clinical factors that are associated with disease sev…
Bethesda, United States
Cystinosis
Cystinosis is an inherited disease resulting in poor growth and kidney failure. There is no known cure for cystinosis, a…
Bethesda, United States